Sanofi and Regeneron score second-round victory for Praluent

Regeneron Pharmaceuticals and Sanofi announced today on a press release that the United States Court of Appeals for the Federal Circuit has suspended the court ruling blocking the marketing of Praluent (alirocumab). The ruling has overturned the judgment in the first instance in favor of Amgen, which had sued the two groups over alleged patent violation on the PCSK9 antibodies (proprotein convertase subtilisin/kexin type 9). Praluent was the first PCSK9 treatment approved in the US to treat LDL hypercholesterolemia.
(Source Sanofi)